Close this search box.
Follow us




Thrombosis occurs when a blood clot forms inside a blood vessel, thrombosis causes blocking of the blood flow through the circulatory system and leads

to serious health issues. Mostly the pathology pathway of ischemic heart disease and ischemic stroke is attributed to thrombosis, which makes thrombosis as one of the most important cause of Cardiovascular diseases. Cardiovascular diseases (CVDs) represent a group of disorders of the heart and blood vessels. Some CVDs which thrombosis is a potential cause of them are: coronary heart disease, cerebrovascular disease and peripheral arterial disease. An estimation has reported that about 17.9 million deaths each year are underlying by cardiovascular diseases, which make cardiovascular diseases (CVDs) the leading cause of death globally. Direct oral anticoagulants (DOACs) are prescribed for prevention and treatment of various cardiovascular diseases (CVDs). Recently direct oral anticoagulants (DOACs) are becoming interesting alternatives to the traditional standard of care in anticoagulation, vitamin K antagonist. Prior to 2010, the only approved oral anticoagulant on the market was warfarin, but since then that the first DOACs were approved, led DOACs to be as a leading therapeutic option, due to their better safety and effectiveness which make them more convenient treatment options for patients and clinicians in thromboembolic settings.

Hence, one of Parsian’s fields of activity is research and development in cardiovascular diseases (CVDs) to manufacture active pharmaceutical ingredients (API) and Granules of direct oral anticoagulants (DOACs) with the highest global standards to help patients having cardiovascular diseases (CVDs) to be cured in a better way by the latest guidelines and with the lowest adverse effects.





Cas No: 936623-90-4

Mechanism Of Action: Sacubitril/valsartan is a medication that exerts its effects through the dual inhibition of neprilysin, an enzyme responsible for degrading certain peptides, and



Cas No: 274693-27-5

Mechanism Of Action: Ticagrelor exerts its pharmacological effects by binding to a specific site on the P2Y12 receptor, which is different from the ADP binding



Cas No: 503612-47-3

Mechanism Of Action: It’s a highly selective and reversible direct inhibitor of free and clot-bound factor Xa, the final enzyme in the coagulation cascade that is



Cas No: 366789-02-8

Mechanism Of Action: It’s a selective inhibitor of factor Xa (FXa), and is an inhibitor of free FXa and prothrombinase activity, and indirectly inhibits platelet aggregation